Description
Breo (fluticasone furoate and vilanterol) is a respiratory medications and inhalers agent listed in our Respiratory medications and inhalers directory and prescribed for specified asthma or reversible-airway conditions and chronic obstructive pulmonary disease (1.1) (2.1). Administered via the respiratory (inhalation) route, Breo is available for delivery to U.S. residents through Canadian Pharmacy Store with a valid prescription. Review the clinical fact table, dosage directions, cautions, drug interactions, side effects, and official regulatory sources below.
Breo is a medication containing the active pharmaceutical ingredient fluticasone furoate and vilanterol, classified pharmacologically as a respiratory medications and inhalers agent (2.1). It is clinically indicated for the management of specified asthma or reversible-airway conditions and chronic obstructive pulmonary disease as part of a comprehensive treatment plan supervised by a licensed healthcare provider (2.1).
Within the Respiratory medications and inhalers section of our catalogue, patients and prescribers frequently review Breo alongside related therapies such as Relvar (Fluticasone Furoate / Vilanterol), Arnuity (Fluticasone Furoate), Veramyst (Fluticasone Furoate), and Avamys (Fluticasone Furoate).
Official Indications and Usage
Fluticasone Furoate/Vilanterol Ellipta is a combination of fluticasone furoate, a corticosteroid, and vilanterol, a long‑acting beta-2 adrenergic agonist (LABA), indicated for (1.1):
- The maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
- The maintenance treatment of asthma in patients aged 5 years and older.
Limitations of use: Not indicated for relief of acute bronchospasm.
Mechanism of Action and Pharmacology
Fluticasone Furoate/Vilanterol Ellipta Fluticasone Furoate/Vilanterol Ellipta contains both fluticasone furoate and vilanterol. The mechanisms of action described below for the individual components apply to Fluticasone Furoate/Vilanterol Ellipta. These drugs represent 2 different classes of medications (an ICS and a LABA), each having different effects on clinical and physiological indices. Fluticasone Furoate Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is approximately 29.9 times that of dexamethasone and 1.7 times that of fluticasone propionate. (1.1) (1.1)
What is Asthma?
Asthma involves inflammation and narrowing of the airways. Controller and quick-relief treatments have distinct roles in an individualized action plan. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete Asthma condition guide for appointment questions and related therapies (3.1).
What is COPD?
Chronic obstructive pulmonary disease causes persistent breathing limitation. Treatment can include inhaled medicines, smoking cessation, rehabilitation, and an exacerbation plan. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete COPD condition guide for appointment questions and related therapies (3.1).
Ordering Breo from Canada for U.S. Delivery
U.S. patients can order Breo (Vilanterol Trifenatate, Fluticasone) in U.S. dollars with a valid prescription from a U.S.-licensed clinician. Your card is only charged after your prescription passes pharmacist safety checks and is ready to ship.
Step 1
Send Your Prescription
- Valid Rx required from a U.S.-licensed physician, NP, or PA (Rx rules).
- Upload Rx online, request a pharmacy transfer, or have your doctor fax (844) 666 – 6819.
- Order up to a 90-day personal-use supply per shipment (refill planning).
Step 2
Pharmacist Safety Check
- Multi-point dosing and interaction review completed in under 1 business day.
- Mandatory licensed pharmacist consultation via phone, voicemail, or text before dispatch.
- Verified under our Pharmacy Safety Standards.
Step 3
$14.99 USD Tracked Parcel
- Packed in discreet protective packaging for a flat $14.99 USD per order ($29.99 if combined with cold-chain).
- Tracked via Canada Post and USPS: 3 to 7 business days from Canada (7 to 14 days from international partners).
- Review full shipping and delivery details.
Step 4
U.S. Street Delivery & Payment
- Delivered to any physical U.S. street address with signature upon delivery (no P.O. Boxes).
- You see and approve the country of origin upfront before your card is charged.
- Report any delayed or damaged parcel within 48 hours for prompt resolution.
Fact Table
| Clinical Specification | Details |
|---|---|
| Brand / Product Name | Breo |
| Chemical / Generic Name | Fluticasone Furoate And Vilanterol |
| Pharmacological Class | Respiratory medications and inhalers agent |
| Therapeutic Category | Respiratory medications and inhalers |
| Same-Ingredient Catalogue Entries | Relvar (Fluticasone Furoate / Vilanterol), Arnuity (Fluticasone Furoate), Veramyst (Fluticasone Furoate), Avamys (Fluticasone Furoate) |
| Molecular Formula | C27H29F3O6S (2.1) |
| Molecular Weight | 538.6 g/mol (2.1) |
| Bioavailability | ~15.2% (1.1) |
| Elimination Half-Life | ~24 hours (1.1) |
| Time to Peak Plasma Level (Tmax) | 0.5 to 1 hour (2.1) |
| Legal Status | Rx-Only (Prescription Required) |
| Regulatory Reference Authorities | U.S. FDA (DailyMed), Health Canada (DPD), NIH PubChem, NLM MedlinePlus |
| Routes of Administration | Respiratory (Inhalation) |
| Dosage Forms & Strengths | Inhalation powder; 50 mcg fluticasone furoate and 25 mcg vilanterol (50/25 mcg) per actuation |
| Primary Indications | Specified Asthma Or Reversible-Airway Conditions And Chronic Obstructive Pulmonary Disease |
| Pregnancy & Breastfeeding | Consult Doctor / Prescriber before use |
| PubChem CID | 9854489 |
| FDA UNII Identifier | 40AHO2C6DG, JS86977WNV |
| NLM RxNorm Concept ID (RxCUI) | 1424889, 1648788 |
| FDA Application License | NDA204275 |
| Official DailyMed SetID | 3a761487-c300-451a-8537-3196c00c11b5 |
| Catalogue Index Links | Letter B Index · All Medications · All Categories |
Directions
Dosage and Administration Overview
- For oral inhalation only.
- Maintenance treatment of COPD: 1 actuation of Fluticasone Furoate/Vilanterol Ellipta 100/25 mcg once daily administered by oral inhalation. (1.1)
Presentations and Strengths
Inhalation powder (1.1):
- 50 mcg fluticasone furoate and 25 mcg vilanterol (50/25 mcg) per actuation.
Administration Guidance
Administer Breo strictly via the prescribed inhalation device according to the schedule set by your healthcare provider (1.1). Prime, load, inhale, and clean the inhaler exactly as shown in the manufacturer’s patient leaflet. If using an inhaled corticosteroid preparation, rinse your mouth with water and spit out after each dose when directed to reduce local throat irritation.
Missed Dose Guidance
If you miss a scheduled dose of Breo, follow the missed-dose instructions in the official patient leaflet or ask your pharmacist. Do not double the next dose to make up for a missed dose (2.1).
Ingredients
Active Pharmaceutical Ingredient
The active ingredient in Breo is fluticasone furoate and vilanterol (molecular formula C27H29F3O6S, molecular weight 538.6 g/mol) (2.1) (2.1). Other catalogue entries containing fluticasone furoate include Relvar (Fluticasone Furoate / Vilanterol), Arnuity (Fluticasone Furoate), Veramyst (Fluticasone Furoate), and Avamys (Fluticasone Furoate).
Excipients and Formulation Carriers
Film coatings, stabilizers, and inactive carriers vary by strength and manufacturer presentation. If you have a known allergy to lactose, dyes, sulfites, or specific preservatives, ask our pharmacist to check the exact excipient list for your selected package (2.1).
Cautions and important safety information
Contraindications
Fluticasone Furoate/Vilanterol Ellipta is contraindicated in the following conditions (1.1):
- Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required.
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, vilanterol, or any of the excipients.
Key Clinical Precautions
Before starting or continuing Breo, discuss your complete medical history with your healthcare provider. Key clinical cautions include (1.1):
- Increased susceptibility to infection: Therapies that modulate immune or metabolic pathways can increase the risk of bacterial, mycotic (fungal), viral, or opportunistic infections. Report fever, persistent cough, painful urination, or localized infection promptly.
- Diabetic ketoacidosis (DKA): Ketoacidosis, a serious condition requiring urgent hospitalization, has been reported even when blood glucose readings are below 250 mg/dL. Risk factors include acute febrile illness, reduced caloric or fluid intake, pancreatic disorders, surgery, and insulin dose reduction.
- Hypersensitivity and anaphylaxis: Serious allergic reactions, including anaphylaxis, angioedema, and severe rash, have been reported. Discontinue use and seek immediate medical care if swelling of the face, lips, tongue, or throat or difficulty breathing occurs.
- Angioedema: Swelling of the face, extremities, lips, tongue, glottis, or larynx can occur at any time during treatment. Airway-involving angioedema requires emergency medical intervention.
- Hypotension and volume depletion: Intravascular volume contraction can cause symptomatic low blood pressure, orthostatic dizziness, or fainting, especially in older adults, patients with impaired renal function, or those taking diuretics. Ensure adequate hydration before and during therapy.
- Discontinuation and withdrawal effects: Do not abruptly stop taking this medication without consulting your prescriber. Premature discontinuation or abrupt withdrawal can cause rebound symptoms, disease flare, or increased thrombotic or cardiovascular risk depending on the drug class.
Pregnancy, Lactation, and Special Populations
There are insufficient data on the use of fluticasone furoate/vilanterol Ellipta or its individual components, fluticasone furoate and vilanterol, in pregnant women to inform a drug-associated risk. In an animal reproduction study, fluticasone furoate and vilanterol administered by inhalation alone or in combination to pregnant rats during the period of organogenesis produced no fetal structural abnormalities. The highest fluticasone furoate and vilanterol doses in this study were approximately 5 and 40 times the maximum recommended human daily inhalation doses (mrhdid) of 200 and 25 mcg, respectively. (1.1)
Interactions
Official Drug Interaction Overview
- Strong cytochrome P450 3A4 inhibitors (e.g., ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects.
- Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system.
- Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm.
- Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with non-potassium-sparing diuretics may worsen with concomitant beta-agonists. (1.1)
Important Interaction Categories
Concomitant use of Breo with certain prescription medications, over-the-counter drugs, or supplements can alter how the medication works or increase the risk of side effects. Important interaction categories to review with your prescriber and pharmacist include (2.1):
- Potassium supplements, potassium-sparing diuretics (such as Aldactone (Spironolactone), eplerenone, triamterene, or amiloride), and salt substitutes: Concomitant use can lead to clinically significant hyperkalemia (elevated serum potassium). Regular electrolyte monitoring is recommended.
- Monoamine oxidase inhibitors (MAOIs, such as phenelzine, tranylcypromine, selegiline, or linezolid): Concomitant use or use within 14 days of stopping an MAOI can cause severe drug interactions, including hypertensive crisis, serotonin syndrome, or enhanced hypoglycemic and central nervous system effects.
- Strong CYP3A4 inhibitors and inducers (such as ketoconazole, itraconazole, clarithromycin, ritonavir, rifampin, carbamazepine, phenytoin, or St. John’s wort): Co-administration with strong CYP3A4 inhibitors can significantly increase plasma concentrations and side-effect risk, whereas CYP3A4 inducers can decrease systemic exposure and reduce efficacy.
Side effects
Like all medications, Breo can cause side effects, although not everyone experiences them. Commonly reported side effects in clinical trials and official labeling include (1.1):
- Headache: Commonly reported during initial treatment; often improves as your body adjusts to the medication.
- Abdominal discomfort or stomach pain: Mild gastrointestinal upset may occur; report severe, persistent, or radiating abdominal pain promptly.
- Skin rash: Mild skin eruptions can occur; seek immediate care if a rash blisters, peels, or is accompanied by fever.
- Cough or upper respiratory symptoms (nasopharyngitis): Common mild respiratory symptoms reported in clinical studies.
Clinical Trial and Postmarketing Adverse Reactions
The following clinically significant adverse reactions are described elsewhere in labeling (1.1):
- Serious Asthma-Related Events - Hospitalizations, Intubations, Death.
- Oropharyngeal Candidiasis.
- Pneumonia.
- Immunosuppression and Risk of Infections.
- Hypercorticism and Adrenal Suppression.
- Paradoxical Bronchospasm.
- Cardiovascular Effects.
- Reduction in Bone Mineral Density.
- Growth Effects.
- Glaucoma and Cataracts Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
When to Seek Immediate Medical Attention
Contact your physician or seek urgent medical care if you experience signs of a severe allergic reaction (hives, difficulty breathing, or swelling of the face, lips, tongue, or throat), severe dizziness or fainting, unexplained severe pain, or any sudden change in your clinical symptoms (2.1).
Storage and handling
Fluticasone Furoate/Vilanterol Ellipta is supplied as a disposable light grey and pale blue plastic inhaler containing 2 foil strips, each with 30 blisters. One strip contains fluticasone furoate (100 or 200 mcg per blister), and the other strip contains vilanterol (25 mcg per blister). A blister from each strip is used to create 1 dose. The inhaler is packaged within a moisture‑protective foil tray with a desiccant and a peelable lid. Store in a dry place away from direct heat or sunlight. (1.1)
Store Breo in its original container at controlled room temperature away from excess heat, direct light, and moisture (such as bathroom cabinets), and keep out of reach of children and pets (1.1).
Frequently Asked Questions About Breo
What is Breo and what active ingredient does it contain?
Breo is a respiratory medications and inhalers agent containing the active pharmaceutical ingredient fluticasone furoate and vilanterol (chemical formula C27H29F3O6S). It is supplied for respiratory (inhalation) administration and requires a valid prescription where applicable.
How does Breo work in the body?
Fluticasone Furoate/Vilanterol Ellipta Fluticasone Furoate/Vilanterol Ellipta contains both fluticasone furoate and vilanterol. The mechanisms of action described below for the individual components apply to Fluticasone Furoate/Vilanterol Ellipta. These drugs represent 2 different classes of medications (an ICS and a LABA), each having different effects on clinical and physiological indices.
What conditions is Breo prescribed to treat?
Breo is primarily indicated for specified asthma or reversible-airway conditions and chronic obstructive pulmonary disease. Your prescribing clinician determines the appropriate indication, strength, and treatment duration based on your individual diagnosis and medical history.
How should I take or use Breo?
Follow the exact dosage, frequency, and administration instructions printed on your prescription label. Breo is administered via the respiratory (inhalation) route. Inhale or administer it consistently at the same time(s) as directed, and never adjust your dose or stop therapy without speaking with your prescriber.
What are the most common side effects of Breo?
Commonly reported side effects of Breo include headache, abdominal pain, rash, and cough. Most mild side effects improve as your body adjusts to treatment, but you should notify your doctor or pharmacist if symptoms persist or worsen.
What medications or substances can interact with Breo?
Important interaction categories for Breo include potassium-containing products, monoamine oxidase inhibitors, and medicines that strongly affect CYP3A enzymes. Always share a complete list of your prescription drugs, over-the-counter medicines, vitamins, and herbal supplements with your pharmacist before starting treatment.
Can Breo be used during pregnancy or breastfeeding?
If you are pregnant, planning to become pregnant, or breastfeeding, consult your prescribing physician before using Breo to weigh the clinical benefits and potential risks.
Do I need a prescription to buy Breo online from Canada?
Yes. A valid prescription written by a U.S.-licensed physician, nurse practitioner, or physician assistant is required to buy Breo (Vilanterol Trifenatate, Fluticasone) through our licensed Canadian pharmacy partners. Valid prescriptions go through multiple safety checks in less than 1 business day, followed by a mandatory request to speak with a licensed pharmacist for a consultation (watch your phone, voicemails, and text messages).
Does Breo have a generic equivalent (Vilanterol Trifenatate, Fluticasone) at a Canada pharmacy?
Currently, Breo (Vilanterol Trifenatate, Fluticasone) is dispensed in our catalogue as a brand-name formulation. Check our Vilanterol Trifenatate, Fluticasone active ingredient hub for updates as licensed generic presentations become available.
How is Breo shipped to U.S. residents, and how much does shipping cost?
Breo ships in discreet protective packaging at a flat rate of $14.99 USD per order via Canada Post and USPS with full tracking (if combined in the same order with a cold-chain item, total shipping is $29.99 USD in a larger container). Once your valid prescription passes safety checks (<1 business day) and you respond to the mandatory licensed pharmacist consultation request via phone, voicemail, or text message, delivery takes 3 to 7 business days from Manitoba, Canada (or 7 to 14 business days from licensed partner pharmacies in the UK, Singapore, and Mauritius). You see and choose the country of origin before you pay, and your Visa, Mastercard, or Discover card is only charged when your order is ready to ship.
How can I send or transfer my Breo prescription, or ask about an unlisted strength?
You can upload a clear photo or PDF of your Breo prescription online, request a prescription transfer or direct prescriber coordination from our team, or have your prescriber fax the prescription directly to (844) 666 – 6819. You may order up to a 90-day personal-use supply per shipment. If you do not see your exact prescribed strength or manufacturer listed, call 1-888-868-1920 and our staff will check availability across our licensed pharmacy partners.
References & Official Sources
Clinical, pharmacological, and safety facts for Breo (Vilanterol Trifenatate / Fluticasone Furoate) are compiled directly from official regulatory prescribing labels and primary biomedical databases:
- (1.1) Fluticasone Furoate and Vilanterol. U.S. National Library of Medicine / U.S. Food and Drug Administration (DailyMed). Official U.S. FDA / DailyMed Structured Product Labeling (SPL). (Accessed 2026-10-29).
- (2.1) PubChem Compound Summary for cid 9854489 (Fluticasone Furoate). National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine. Official regulatory & clinical reference. (Accessed 2026-10-29).
- (3.1) MedlinePlus Medical Encyclopedia: Asthma. MedlinePlus / National Library of Medicine. U.S. National Library of Medicine, MedlinePlus Drug & Health Information. (Accessed 2026-10-29).
- (4.1) MedlinePlus Medical Encyclopedia: COPD. MedlinePlus / National Library of Medicine. U.S. National Library of Medicine, MedlinePlus Drug & Health Information. (Accessed 2026-10-29).
- (5.1) Health Canada Drug Product Database (DPD), Authorized Product Records. Health Canada / Government of Canada. Health Canada Drug Product Database & Official Product Monograph. (Accessed 2026-10-29).
